CellaVision AB (CHIX:CEVIS) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 07, 2026)


CHIX:CEVIS CellaVision AB CHIX:CEVIS
95 GF Score
Price kr160.20
GF Value kr231.79
! 1 Warning Sign
View Full Analysis

What is CellaVision AB 5-Year Yield-on-Cost %?

CellaVision AB CHIX:CEVIS 95 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus rates CHIX:CEVIS with a GF Score™ of 95/100 and a GF Value™ of kr231.79. The stock has 1 warning sign investors should review. Among 328 Medical Devices & Instruments companies, CellaVision AB ranks worse than 56.1% on this metric.

CellaVision AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for CellaVision AB's 5-Year Yield-on-Cost % or its related term are showing as below:


During the past 13 years, CellaVision AB's highest Yield on Cost was 2.42. The lowest was 0.16. And the median was 0.93.


CHIX:CEVIs's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.355
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

CellaVision AB  (CHIX:CEVIs) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


CellaVision AB 5-Year Yield-on-Cost % Related Terms


CHIX:CEVIS vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison

For the Medical Devices subindustry, CellaVision AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CellaVision AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where CellaVision AB's 5-Year Yield-on-Cost % falls into.


CHIX:CEVIS
95GF Score
CellaVision AB CHIX:CEVIS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellaVision AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of CellaVision AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
CellaVision AB (CHIX:CEVIS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 07, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellaVision AB and its competitors. Over the past decade, CellaVision AB's 5-Year Yield-on-Cost % has ranged from 0.16 to 2.42. According to the industry distribution chart, CellaVision AB ranks #184 out of 328 companies in the Medical Devices & Instruments industry, placing it in the top 56.1%.
Is CellaVision AB's 5-Year Yield-on-Cost % too high?
CellaVision AB's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 2.42. Based on the distribution chart, CellaVision AB ranks #184 out of 328 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #184 out of 328 companies for 5-Year Yield-on-Cost %. This places CellaVision AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Historically, CellaVision AB's own 5-Year Yield-on-Cost % has ranged from 0.16 to 2.42 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
CellaVision AB (CHIX:CEVIS) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is kr231.79, compared to a current price of kr160.20 — trading 30.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. CellaVision AB's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For CellaVision AB (CHIX:CEVIS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellaVision AB (CHIX:CEVIS) Overvalued in 2026?

Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued. The current stock price of kr160.20 is trading 30.9% below its estimated GF Value™ of kr231.79.

Key valuation signals for CHIX:CEVIS:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: kr231.79 vs. price of kr160.20 (30.9% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the CHIX:CEVIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CellaVision AB Business Description

Address Mobilvagen 12, Lund, SWE, 22362
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
95GF Score

Get the complete analysis for CHIX:CEVIS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr160.20
Price
kr231.79
GF Value